Trial Profile
A prospective, single centre, phase II study to evaluate chronomodulated capecitabine and oxaliplatin (XELOX) regimen in untreated metastatic colorectal cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 09 Jul 2017 New trial record
- 01 Jul 2017 All the patients have been treated between September 2012 and September 2014, according to an article published in the Cancer Chemotherapy and Pharmacology.